铁基 MOFs 在生物医学应用中的现状

IF 3.597 Q2 Pharmacology, Toxicology and Pharmaceutics
MedChemComm Pub Date : 2023-09-29 DOI:10.1039/D3MD00416C
Hanping Yang, Donghui Liao, Zhidong Cai, Yuelin Zhang, Alireza Nezamzadeh-Ejhieh, Mingbin Zheng, Jianqiang Liu, Zhi Bai and Hailiang Song
{"title":"铁基 MOFs 在生物医学应用中的现状","authors":"Hanping Yang, Donghui Liao, Zhidong Cai, Yuelin Zhang, Alireza Nezamzadeh-Ejhieh, Mingbin Zheng, Jianqiang Liu, Zhi Bai and Hailiang Song","doi":"10.1039/D3MD00416C","DOIUrl":null,"url":null,"abstract":"<p >Recently nanoparticle-based platforms have gained interest as drug delivery systems and diagnostic agents, especially in cancer therapy. With their ability to provide preferential accumulation at target sites, nanocarrier-constructed antitumor drugs can improve therapeutic efficiency and bioavailability. In contrast, metal–organic frameworks (MOFs) have received increasing academic interest as an outstanding class of coordination polymers that combine porous structures with high drug loading <em>via</em> temperature modulation and ligand interactions, overcoming the drawbacks of conventional drug carriers. Fe<small><sup>III</sup></small>-based MOFs are one of many with high biocompatibility and good drug loading capacity, as well as unique Fenton reactivity and superparamagnetism, making them highly promising in chemodynamic and photothermal therapy, and magnetic resonance imaging. Given this, this article summarizes the applications of Fe<small><sup>III</sup></small>-based MOFs in three significant fields: chemodynamic therapy, photothermal therapy and MRI, suggesting a logical route to new strategies. This article concludes by summarising the primary challenges and development prospects in these promising research areas.</p>","PeriodicalId":88,"journal":{"name":"MedChemComm","volume":" 12","pages":" 2473-2495"},"PeriodicalIF":3.5970,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Current status of Fe-based MOFs in biomedical applications\",\"authors\":\"Hanping Yang, Donghui Liao, Zhidong Cai, Yuelin Zhang, Alireza Nezamzadeh-Ejhieh, Mingbin Zheng, Jianqiang Liu, Zhi Bai and Hailiang Song\",\"doi\":\"10.1039/D3MD00416C\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Recently nanoparticle-based platforms have gained interest as drug delivery systems and diagnostic agents, especially in cancer therapy. With their ability to provide preferential accumulation at target sites, nanocarrier-constructed antitumor drugs can improve therapeutic efficiency and bioavailability. In contrast, metal–organic frameworks (MOFs) have received increasing academic interest as an outstanding class of coordination polymers that combine porous structures with high drug loading <em>via</em> temperature modulation and ligand interactions, overcoming the drawbacks of conventional drug carriers. Fe<small><sup>III</sup></small>-based MOFs are one of many with high biocompatibility and good drug loading capacity, as well as unique Fenton reactivity and superparamagnetism, making them highly promising in chemodynamic and photothermal therapy, and magnetic resonance imaging. Given this, this article summarizes the applications of Fe<small><sup>III</sup></small>-based MOFs in three significant fields: chemodynamic therapy, photothermal therapy and MRI, suggesting a logical route to new strategies. This article concludes by summarising the primary challenges and development prospects in these promising research areas.</p>\",\"PeriodicalId\":88,\"journal\":{\"name\":\"MedChemComm\",\"volume\":\" 12\",\"pages\":\" 2473-2495\"},\"PeriodicalIF\":3.5970,\"publicationDate\":\"2023-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MedChemComm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2023/md/d3md00416c\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MedChemComm","FirstCategoryId":"1085","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2023/md/d3md00416c","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

近年来,基于纳米粒子的平台作为药物输送系统和诊断试剂,特别是在癌症治疗中引起了人们的兴趣。纳米载体构建的抗肿瘤药物具有在靶点优先积累的能力,可以提高治疗效率和生物利用度。相比之下,金属有机框架(MOFs)作为一类杰出的配位聚合物,通过温度调节和配体相互作用将多孔结构与高药物负载结合起来,克服了传统药物载体的缺点,受到了越来越多的学术关注。基于feii的mof具有较高的生物相容性和良好的载药能力,以及独特的Fenton反应性和超顺磁性,在化学动力学、光热治疗和磁共振成像等领域具有广阔的应用前景。鉴于此,本文总结了基于feii的mof在化学动力治疗、光热治疗和MRI三个重要领域的应用,提出了新的策略的逻辑路径。本文最后总结了这些有前景的研究领域面临的主要挑战和发展前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Current status of Fe-based MOFs in biomedical applications

Current status of Fe-based MOFs in biomedical applications

Current status of Fe-based MOFs in biomedical applications

Recently nanoparticle-based platforms have gained interest as drug delivery systems and diagnostic agents, especially in cancer therapy. With their ability to provide preferential accumulation at target sites, nanocarrier-constructed antitumor drugs can improve therapeutic efficiency and bioavailability. In contrast, metal–organic frameworks (MOFs) have received increasing academic interest as an outstanding class of coordination polymers that combine porous structures with high drug loading via temperature modulation and ligand interactions, overcoming the drawbacks of conventional drug carriers. FeIII-based MOFs are one of many with high biocompatibility and good drug loading capacity, as well as unique Fenton reactivity and superparamagnetism, making them highly promising in chemodynamic and photothermal therapy, and magnetic resonance imaging. Given this, this article summarizes the applications of FeIII-based MOFs in three significant fields: chemodynamic therapy, photothermal therapy and MRI, suggesting a logical route to new strategies. This article concludes by summarising the primary challenges and development prospects in these promising research areas.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
MedChemComm
MedChemComm BIOCHEMISTRY & MOLECULAR BIOLOGY-CHEMISTRY, MEDICINAL
CiteScore
4.70
自引率
0.00%
发文量
0
审稿时长
2.2 months
期刊介绍: Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry. In 2020, MedChemComm will change its name to RSC Medicinal Chemistry. Issue 12, 2019 will be the last issue as MedChemComm.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信